ReviewExpert opinion on therapeutic targets2008
Tissue-type plasminogen activator as a therapeutic target in stroke.
Review in Expert opinion on therapeutic targets, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03519737 (A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Aureva Transcranial Ultrasound Device With Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke), which is not on this map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Aureva Transcranial Ultrasound Device With Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke (TRUST)
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Serpin family proteins as potential biomarkers and therapeutic drugs in stroke: A systematic review and meta-analysis on clinical/preclinical studies.CNS neuroscience & therapeutics · 2023Pooled it
- Multiscale photoacoustic imaging of stroke in preclinical models and future directions toward clinical translation [Invited].Biomedical optics express · 2026Review
- Article
- Impact of the Chronic Ischemic Stroke Microenvironment on Silk Fibroin Hydrogel Biodegradation andACS omega · 2026Article
- Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.Communications medicine · 2026Article
- Reperfusion Therapies and Post-Stroke Seizures: Evidence, Mechanisms and Clinical Implications-A Narrative Review.The Malaysian journal of medical sciences : MJMS · 2025Review
- Dual role of vascular endothelial growth factor-C in post-stroke recovery.The Journal of experimental medicine · 2025Article
- Beyond the hype: re-evaluating efficacy metrics and modeling rigor for MSC-EVs-based therapy in acute brain injury.Frontiers in medicine · 2025Review
- A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch.Stroke (Hoboken, N.J.) · 2024Review
- Repurposing the KTranslational stroke research · 2024Article
- Therapeutic management of ischemic stroke.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Review
- Proteoform-Resolved Profiling of Plasminogen Activation Reveals Novel Abundant Phosphorylation Site and Primary N-Terminal Cleavage Site.Molecular & cellular proteomics : MCP · 2024Article
- Characterization of Enlarged Tongues in Cloned Piglets.Current issues in molecular biology · 2023Article
- Evolving Clinical-Translational Investigations of Cerebroprotection in Ischemic Stroke.Journal of clinical medicine · 2023Review
- Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy.Materials today. Bio · 2023Review
- The BDNF mimetic R-13 attenuates TBI pathogenesis using TrkB-related pathways and bioenergetics.Biochimica et biophysica acta. Molecular basis of disease · 2023Article
- Development and validation of a nomogram model for predicting unfavorable functional outcomes in ischemic stroke patients after acute phase.Frontiers in aging neuroscience · 2023Article
- Protection against brain injury after ischemic stroke by intravenous human amnion epithelial cells in combination with tissue plasminogen activator.Frontiers in neuroscience · 2023Article
- Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications.Therapeutic advances in psychopharmacology · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIschemic stroke is a leading cause of morbidity and mortality worldwide and recombinant human tissue-type plasminogen activator (tPA) is the prominent therapeutic among very few therapeutics used in its treatment. Due to complications attributed to the drug, most notably transformation of ischemia to hemorrhage, tPA is only used in a small number of ischemic stroke cases, albeit significantly more often in specialized stroke centers.
objectiveWhat are the mechanisms of tPA action and side effects in ischemic stroke, and can the knowledge about these mechanisms aid in making tPA a more efficacious and safe therapeutic or in developing alternative therapeutics?
methodstPA use and alternative/combination therapies in acute ischemic stroke treatment are summarized. The review focuses on literature concerning tPA neurotoxicity and its implications for further development of tPA as a stroke therapeutic. RESULTS/
conclusionExogenously administered recombinant tPA and endogenous tPA have both turned into promising therapeutic targets for the stroke patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.